Developer docs
API playgroundTry for free, no card

Search company profiles

Cure Sanfilippo Foundation

Full company profile

uuid005qoer

Namestring
Cure Sanfilippo Foundation
Legal namestring
Cure Sanfilippo Foundation
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Cure Sanfilippo Foundation is a 501(c)(3)-style nonprofit foundation founded in 2013 and headquartered in Columbia, South Carolina, with a stated mission to advocate for and fund research directed toward a cure for children with Sanfilippo Syndrome, a rare terminal neurodegenerative disease affecting an estimated 15,000 children globally. It operates with a small staff (1-10 employees) and serves four principal constituencies: families of affected children, academic and clinical researchers, physicians diagnosing and managing Sanfilippo patients, and biotechnology and pharmaceutical companies developing therapies. Its core service areas are accelerating research, uniting and supporting families, driving collaboration across stakeholders, and raising disease awareness.

Short descriptiontext

Cure Sanfilippo Foundation is a nonprofit foundation funding research toward a cure for Sanfilippo Syndrome, serving affected families, researchers, clinicians, and biotech companies through research grants, the global SanfilippoLINK registry, the ADVANCE conference, the Aurora grief support program, and FDA-facing caregiver preference research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersScarborough, Canada
HQ citystring
Scarborough
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease research funding, patient advocacy foundation, clinical research registry, pediatric neurodegenerative disease, family support services
Industry2 codes
1Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
CodeBPAGACAAPrimaryYes
2Grantmaking & Philanthropic Funds (Institutional Donors)
CodeBPADAOABPrimaryNo
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Grantmaking and Giving Services8132
SIC code2 codes
  • Services-Health Services8000
  • Services-Social Services8300
Product category
Nonprofit Rare Disease Patient Advocacy
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model6 records
1Individual Donations
TypeGrants Donations
Description

One-time and recurring donations from individuals supporting the mission to cure Sanfilippo Syndrome. Donors can give once or set up monthly recurring donations.

curesanfilippofoundation.org
2Corporate Giving & Matching
TypeGrants Donations
Description

Corporate giving programs and employer donation matching programs for employees who donate.

curesanfilippofoundation.org
3Cryptocurrency Donations
TypeGrants Donations
Description

Acceptance of cryptocurrency donations.

curesanfilippofoundation.org
4IRA, Stocks & Bequests
TypeGrants Donations
Description

Planned giving options including IRA distributions, stock donations, and bequests.

curesanfilippofoundation.org
5Online Store / Merchandise
TypeHardware Sales
Description

Sale of branded merchandise including t-shirts, hats, and family boutiques where supporters can purchase family-specific fundraising items.

curesanfilippofoundation.org
6Event Fundraising
TypeGrants Donations
Description

Virtual and in-person events including 5K runs, streaming fundraisers through Tiltify, and hosted events.

curesanfilippofoundation.org
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

Cure Sanfilippo Foundation is a nonprofit patient advocacy organization that funds research toward treatments and a cure for Sanfilippo Syndrome, a rare terminal neurodegenerative childhood disease. It operates SanfilippoLINK, a global patient registry and clinical research platform, has funded 50+ research projects and multiple clinical trials, and provides counselor-led family support, educational webinars, clinical care guidelines, and the annual ADVANCE conference connecting families, researchers, clinicians, and biotechs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • $20 million raised since 2013
+4 more records
Product overview1 text field

Cure Sanfilippo Foundation operates as a patient advocacy and research organization rather than a traditional product company. Its core offerings include SanfilippoLINK, a global patient registry platform for clinical research; ADVANCE, an annual virtual conference connecting families and researchers; the Aurora Program providing counselor-led grief support groups; Sanfilippo Speak webinar series for family education; Clinical Care Guidelines for disease management; and a Caregiver Preference Study. The organization also operates an online store for awareness merchandise and family boutiques. All offerings are oriented toward accelerating research, supporting affected families, and raising awareness for Sanfilippo Syndrome.

Product and service5 records
1SanfilippoLINK
CategoryClinical Research Platform
Description

A global clinical research and patient registry platform dedicated to all forms of Sanfilippo syndrome, open to participants worldwide to advance understanding and treatments. It supports researchers and biotech companies with patient recruitment, natural history data, and clinical trial design insights.

2ADVANCE Conference
CategoryCommunity Conference
Description

An annual virtual Sanfilippo Community Conference bringing together families, caregivers, scientists, researchers, clinicians, therapists, advocates, biotechs, and supporters for collaboration, information sharing, and Sanfilippo-specific learning sessions.

3Aurora Program
CategoryFamily Support Program
Description

A counselor-led group support program providing grief processing and resilience building for families of children with Sanfilippo Syndrome. Includes Dads' Group, Daytime Open Group, Evening Open Group, and closed counseling groups of 8-10 parents meeting bi-weekly for six months; provided at no cost to partner families.

4Sanfilippo Speak
CategoryEducational Webinar Series
Description

A free family support webinar series providing insights and discussions around topics specific to navigating life with Sanfilippo Syndrome, available to families, caregivers, therapists, educators, and clinicians.

5Clinical Care Guidelines
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Sangrail Biologics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Clinical-stage gene therapy company that picked up Sanfilippo Type B AAV9 gene therapy program (SNG-101, formerly ABO-101 under Abeona Therapeutics). Launched company May 5, 2026.

curesanfilippofoundation.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Conducts Natural History Study of Sanfilippo Syndrome Type IIIC (C-RARE), a remote prospective observational study of participants with MPS IIIC.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Conducts natural history study of Sanfilippo Syndrome Type IIIC in a multi-center, 2-year observational study.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Developing UX111 AAV9 gene therapy for Sanfilippo Type A. Submitted to FDA for accelerated approval. Foundation has been actively advocating for FDA action on this therapy.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

DNL126 (MPS IIIA) program selected for FDA's START pilot program, intended to improve efficiency of drug development.

Strategic tierCoreTypeOthers
Description

Foundation presented Caregiver Preference Study to FDA in March 2020, advocating for non-cognitive based endpoints when evaluating therapies. FDA has engaged on surrogate endpoint agreement for UX111.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

NORD's Caregiver Respite Program provides financial assistance to enable caregivers a break from caregiving responsibilities.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner organization providing family support programs including conference scholarships, bereavement expenses, equipment or medical aids, and travel assistance.

9The BLAIR Connection
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Support site for siblings of terminally-ill children, created by Grey Chapin whose sister Blair passed away from Sanfilippo in 2017.

curesanfilippofoundation.org
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Parent-created network providing wisdom from fellow parents and pediatric care providers to support families caring for seriously-ill children.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Provides free flights and ground transportation for patients to access life-saving medical care, including travel to Sanfilippo-related treatments.

Strategic tierMinorTypeOthers
Description

TSA program assisting travelers with disabilities and medical conditions through Passenger Support Specialists who can provide assistance through security screening.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Parent-led nonprofit focused on Duchenne muscular dystrophy that funds research, advocates at FDA, and operates family support programs. Highly comparable operating model to Cure Sanfilippo's parent-driven, disease-specific structure.

TypeBroad incumbent
Description

Umbrella advocacy organization supporting all rare diseases, including operating the Caregiver Respite Program that partners with Cure Sanfilippo. Comparable as a federal-policy and cross-disease advocacy leader, but operates at a different scale and scope.

TypeBroad incumbent
Description

Public policy advocacy nonprofit focused on accelerating biotech innovation for rare diseases. Comparable to Cure Sanfilippo in FDA/regulatory engagement mission but at an industry-wide rather than disease-specific level.

TypeDirect peer
Description

Spinal muscular atrophy nonprofit that funded research leading to approved gene therapies (Spinraza, Zolgensma, Evrysdi). Closely comparable playbook: rare pediatric neuro disease, parent-founded, FDA advocacy, and direct biotech partnerships.

TypeBroad incumbent
Description

Larger disease-specific nonprofit funding ALS research, supporting families, and advocating at FDA. Demonstrates a more mature version of the model Cure Sanfilippo is building, including clinical care guidelines and biotech partnerships.

TypeDirect peer
Description

Childhood cancer research nonprofit combining research funding, family support, and broad donor engagement. Operates at a larger scale but follows a similar disease-specific research accelerator model Cure Sanfilippo employs for a rare pediatric disease.

TypeOthers
Description

Clinical-stage gene therapy company that previously led ABO-101 (Sanfilippo Type B) before transferring the program to Sangrail. Relevant ecosystem participant as a former biotech partner rather than a comparable peer.

TypeDirect peer
Description

Patient-founded, disease-specific nonprofit that funds research, runs a patient registry, and supports families for a single rare disease (CF). Cure Sanfilippo mirrors this model at a smaller scale, including direct FDA engagement, clinical care guidelines, and biotech partnerships.

TypeDirect peer
Description

Nonprofit supporting all mucopolysaccharidosis (MPS) and related lysosomal storage diseases, including Sanfilippo (MPS III). Provides family support, research funding, and conferences; directly relevant as an adjacent MPS umbrella organization.

TypeBroad incumbent
Description

Rare disease patient advocacy organization focused on education, awareness, and community-building across many conditions. Overlaps with Cure Sanfilippo's awareness and family-support programming but serves a broader constituency.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cure Sanfilippo Foundation

Nonprofit Rare Disease Patient Advocacycuresanfilippofoundation.org

Cure Sanfilippo Foundation is a nonprofit foundation funding research toward a cure for Sanfilippo Syndrome, serving affected families, researchers, clinicians, and biotech companies through research grants, the global SanfilippoLINK registry, the ADVANCE conference, the Aurora grief support program, and FDA-facing caregiver preference research.

What Cure Sanfilippo Foundation does

Cure Sanfilippo Foundation is a 501(c)(3)-style nonprofit foundation founded in 2013 and headquartered in Columbia, South Carolina, with a stated mission to advocate for and fund research directed toward a cure for children with Sanfilippo Syndrome, a rare terminal neurodegenerative disease affecting an estimated 15,000 children globally. It operates with a small staff (1-10 employees) and serves four principal constituencies: families of affected children, academic and clinical researchers, physicians diagnosing and managing Sanfilippo patients, and biotechnology and pharmaceutical companies developing therapies. Its core service areas are accelerating research, uniting and supporting families, driving collaboration across stakeholders, and raising disease awareness.

Cure Sanfilippo Foundation firmographics

Firmographics
Name
Cure Sanfilippo Foundation
Legal name
Cure Sanfilippo Foundation
Website
https://curesanfilippofoundation.org
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Cure Sanfilippo Foundation is a nonprofit foundation funding research toward a cure for Sanfilippo Syndrome, serving affected families, researchers, clinicians, and biotech companies through research grants, the global SanfilippoLINK registry, the ADVANCE conference, the Aurora grief support program, and FDA-facing caregiver preference research.
Ownership category
akta.pro rank

Cure Sanfilippo Foundation industry classification

Industry
Product category
Nonprofit Rare Disease Patient Advocacy
NAICS
Voluntary Health Organizations (813212), Grantmaking and Giving Services (8132)
SIC
Services-Health Services (8000), Services-Social Services (8300)
akta.pro primary industry
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)
akta.pro secondary industry
Grantmaking & Philanthropic Funds (Institutional Donors) (BPADAOAB)

Keywords

  • Rare disease research funding
  • Patient advocacy foundation
  • Clinical research registry
  • Pediatric neurodegenerative disease
  • Family support services

Where Cure Sanfilippo Foundation is headquartered

Location

Headquarters

HQ city
Scarborough
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Cure Sanfilippo Foundation business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. Individual Donations: One-time and recurring donations from individuals supporting the mission to cure Sanfilippo Syndrome. Donors can give once or set up monthly recurring donations.
  2. Corporate Giving & Matching: Corporate giving programs and employer donation matching programs for employees who donate.
  3. Cryptocurrency Donations: Acceptance of cryptocurrency donations.
  4. IRA, Stocks & Bequests: Planned giving options including IRA distributions, stock donations, and bequests.
  5. Online Store / Merchandise: Sale of branded merchandise including t-shirts, hats, and family boutiques where supporters can purchase family-specific fundraising items.
  6. Event Fundraising: Virtual and in-person events including 5K runs, streaming fundraisers through Tiltify, and hosted events.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Cure Sanfilippo Foundation product offering

Product offering

Core offering

Cure Sanfilippo Foundation is a nonprofit patient advocacy organization that funds research toward treatments and a cure for Sanfilippo Syndrome, a rare terminal neurodegenerative childhood disease. It operates SanfilippoLINK, a global patient registry and clinical research platform, has funded 50+ research projects and multiple clinical trials, and provides counselor-led family support, educational webinars, clinical care guidelines, and the annual ADVANCE conference connecting families, researchers, clinicians, and biotechs.

Product overview

Cure Sanfilippo Foundation operates as a patient advocacy and research organization rather than a traditional product company. Its core offerings include SanfilippoLINK, a global patient registry platform for clinical research; ADVANCE, an annual virtual conference connecting families and researchers; the Aurora Program providing counselor-led grief support groups; Sanfilippo Speak webinar series for family education; Clinical Care Guidelines for disease management; and a Caregiver Preference Study. The organization also operates an online store for awareness merchandise and family boutiques. All offerings are oriented toward accelerating research, supporting affected families, and raising awareness for Sanfilippo Syndrome.

Differentiator

Problem solved

Functional benefit

Products and services

  • SanfilippoLINK A global clinical research and patient registry platform dedicated to all forms of Sanfilippo syndrome, open to participants worldwide to advance understanding and treatments. It supports researchers and biotech companies with patient recruitment, natural history data, and clinical trial design insights.
  • ADVANCE Conference An annual virtual Sanfilippo Community Conference bringing together families, caregivers, scientists, researchers, clinicians, therapists, advocates, biotechs, and supporters for collaboration, information sharing, and Sanfilippo-specific learning sessions.
  • Aurora Program A counselor-led group support program providing grief processing and resilience building for families of children with Sanfilippo Syndrome. Includes Dads' Group, Daytime Open Group, Evening Open Group, and closed counseling groups of 8-10 parents meeting bi-weekly for six months; provided at no cost to partner families.
  • Sanfilippo Speak A free family support webinar series providing insights and discussions around topics specific to navigating life with Sanfilippo Syndrome, available to families, caregivers, therapists, educators, and clinicians.
  • Clinical Care Guidelines

Quantifiable outcome

  • $20 million raised since 2013
  • +4 more outcomes

Companies that use Cure Sanfilippo Foundation

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Cure Sanfilippo Foundation technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cure Sanfilippo Foundation partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and minor.

  • Sangrail BiologicscoreStrategic or Co-development Partner · 5 May 2026Clinical-stage gene therapy company that picked up Sanfilippo Type B AAV9 gene therapy program (SNG-101, formerly ABO-101 under Abeona Therapeutics). Launched company May 5, 2026.
  • UT Southwestern Children's Medical CentercoreStrategic or Co-development PartnerConducts Natural History Study of Sanfilippo Syndrome Type IIIC (C-RARE), a remote prospective observational study of participants with MPS IIIC.
  • Hospices Civils De LyoncoreStrategic or Co-development PartnerConducts natural history study of Sanfilippo Syndrome Type IIIC in a multi-center, 2-year observational study.
  • Ultragenyx PharmaceuticalcoreStrategic or Co-development PartnerDeveloping UX111 AAV9 gene therapy for Sanfilippo Type A. Submitted to FDA for accelerated approval. Foundation has been actively advocating for FDA action on this therapy.
  • Denali TherapeuticscoreStrategic or Co-development PartnerDNL126 (MPS IIIA) program selected for FDA's START pilot program, intended to improve efficiency of drug development.
  • FDA (U.S. Food & Drug Administration)coreOthersFoundation presented Caregiver Preference Study to FDA in March 2020, advocating for non-cognitive based endpoints when evaluating therapies. FDA has engaged on surrogate endpoint agreement for UX111.
  • NORD (National Organization for Rare Disorders)minorStrategic or Co-development PartnerNORD's Caregiver Respite Program provides financial assistance to enable caregivers a break from caregiving responsibilities.
  • MPS SocietyminorStrategic or Co-development PartnerPartner organization providing family support programs including conference scholarships, bereavement expenses, equipment or medical aids, and travel assistance.
  • The BLAIR ConnectionminorStrategic or Co-development PartnerSupport site for siblings of terminally-ill children, created by Grey Chapin whose sister Blair passed away from Sanfilippo in 2017.
  • Courageous Parents NetworkminorStrategic or Co-development PartnerParent-created network providing wisdom from fellow parents and pediatric care providers to support families caring for seriously-ill children.
  • Angel Flight NEminorStrategic or Co-development PartnerProvides free flights and ground transportation for patients to access life-saving medical care, including travel to Sanfilippo-related treatments.
  • TSA CaresminorOthersTSA program assisting travelers with disabilities and medical conditions through Passenger Support Specialists who can provide assistance through security screening.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Cure Sanfilippo Foundation competitors and assessment

Company assessment

Direct peers

  • Parent Project Muscular Dystrophy (PPMD): Parent-led nonprofit focused on Duchenne muscular dystrophy that funds research, advocates at FDA, and operates family support programs. Highly comparable operating model to Cure Sanfilippo's parent-driven, disease-specific structure.
  • Cure SMA: Spinal muscular atrophy nonprofit that funded research leading to approved gene therapies (Spinraza, Zolgensma, Evrysdi). Closely comparable playbook: rare pediatric neuro disease, parent-founded, FDA advocacy, and direct biotech partnerships.
  • Alex's Lemonade Stand Foundation: Childhood cancer research nonprofit combining research funding, family support, and broad donor engagement. Operates at a larger scale but follows a similar disease-specific research accelerator model Cure Sanfilippo employs for a rare pediatric disease.
  • Cystic Fibrosis Foundation: Patient-founded, disease-specific nonprofit that funds research, runs a patient registry, and supports families for a single rare disease (CF). Cure Sanfilippo mirrors this model at a smaller scale, including direct FDA engagement, clinical care guidelines, and biotech partnerships.
  • National MPS Society: Nonprofit supporting all mucopolysaccharidosis (MPS) and related lysosomal storage diseases, including Sanfilippo (MPS III). Provides family support, research funding, and conferences; directly relevant as an adjacent MPS umbrella organization.

Broad incumbents

  • National Organization for Rare Disorders (NORD): Umbrella advocacy organization supporting all rare diseases, including operating the Caregiver Respite Program that partners with Cure Sanfilippo. Comparable as a federal-policy and cross-disease advocacy leader, but operates at a different scale and scope.
  • EveryLife Foundation for Rare Diseases: Public policy advocacy nonprofit focused on accelerating biotech innovation for rare diseases. Comparable to Cure Sanfilippo in FDA/regulatory engagement mission but at an industry-wide rather than disease-specific level.
  • ALS Association: Larger disease-specific nonprofit funding ALS research, supporting families, and advocating at FDA. Demonstrates a more mature version of the model Cure Sanfilippo is building, including clinical care guidelines and biotech partnerships.
  • Global Genes: Rare disease patient advocacy organization focused on education, awareness, and community-building across many conditions. Overlaps with Cure Sanfilippo's awareness and family-support programming but serves a broader constituency.

Others

  • Abeona Therapeutics: Clinical-stage gene therapy company that previously led ABO-101 (Sanfilippo Type B) before transferring the program to Sangrail. Relevant ecosystem participant as a former biotech partner rather than a comparable peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Cure Sanfilippo Foundation social profiles

Digital presence

Cure Sanfilippo Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cure Sanfilippo Foundation leadership team

Management profile

Number of profiles

Profiles1 record

Cure Sanfilippo Foundation funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cure Sanfilippo Foundation M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cure Sanfilippo Foundation

What does Cure Sanfilippo Foundation do?

Cure Sanfilippo Foundation is a nonprofit patient advocacy organization that funds research toward treatments and a cure for Sanfilippo Syndrome, a rare terminal neurodegenerative childhood disease. It operates SanfilippoLINK, a global patient registry and clinical research platform, has funded 50+ research projects and multiple clinical trials, and provides counselor-led family support, educational webinars, clinical care guidelines, and the annual ADVANCE conference connecting families, researchers, clinicians, and biotechs.

Is Cure Sanfilippo Foundation a public or private company?

Cure Sanfilippo Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Cure Sanfilippo Foundation founded?

Cure Sanfilippo Foundation was founded in 2013. It employs 1 to 10 people.

Where is Cure Sanfilippo Foundation based?

Cure Sanfilippo Foundation is headquartered in Scarborough, Canada, in the North America region.

How does Cure Sanfilippo Foundation make money?

Six revenue lines are on record. Individual Donations are the primary driver. The others are corporate Giving & Matching, cryptocurrency Donations, IRA, Stocks & Bequests, online Store / Merchandise and event Fundraising.

Who are Cure Sanfilippo Foundation's main competitors?

Direct peers on record are Parent Project Muscular Dystrophy (PPMD), Cure SMA, Alex's Lemonade Stand Foundation, Cystic Fibrosis Foundation and National MPS Society. Broad incumbents are National Organization for Rare Disorders (NORD), EveryLife Foundation for Rare Diseases, ALS Association and Global Genes. Abeona Therapeutics is listed as an others.

Does Cure Sanfilippo Foundation have an API?

No public API is recorded for Cure Sanfilippo Foundation.

What industry is Cure Sanfilippo Foundation in?

Cure Sanfilippo Foundation's product category is Nonprofit Rare Disease Patient Advocacy. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPADAOAB, Grantmaking & Philanthropic Funds (Institutional Donors). Its NAICS code is 813212 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceSpruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesSpruce Biosciences reported Q2 2026 results with a net loss of $16.2 million and cash of $96.3 million. The company anticipates a BLA submission for TA-ERT in Q4 2026 and a $5.5 million strategic investment from patient advocacy groups. It also plans to initiate the TrAnsform confirmatory study in Q4 2026.GurufocusCure Sanfilippo Foundation and National MPS Society Make $5.5 MiSpruce Biosciences announced that the Cure Sanfilippo Foundation and the National MPS Society have agreed to make a combined $5.5 million strategic investment in the company. The funds will be used to partially fund the TA-ERT Expanded Access Program (EAP), aiming to broaden patient access to the investigational therapy for Sanfilippo Syndrome Type B while awaiting potential FDA approval.SprucebioCure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce BiosciencesSpruce Biosciences announced a combined $5.5 million strategic investment from Cure Sanfilippo Foundation and the National MPS Society to fund the TA-ERT Expanded Access Program for Sanfilippo Syndrome Type B. The program, expected to enroll about 10 participants, is planned to start in the fourth quarter of 2026.BioSpaceCure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce BiosciencesSpruce Biosciences announced a combined $5.5 million strategic investment from Cure Sanfilippo Foundation and the National MPS Society to fund the TA-ERT Expanded Access Program for Sanfilippo Syndrome Type B. The program, expected to enroll about 10 participants, is planned to start in the fourth quarter of 2026.YahooCure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce BiosciencesCure Sanfilippo Foundation and the National MPS Society have made a combined $5.5 million strategic investment in Spruce Biosciences to fund an expanded access program for its investigational therapy TA-ERT. The proceeds will support the initiation of this Expanded Access Program (EAP) in the fourth quarter of 2026, aiming to broaden patient access to treatment for Sanfilippo Syndrome Type B while awaiting potential FDA approval.PeoplemagHer Belly Was Hard, Her Diapers Always Full. Why Her Mom Knew Something Was Wrong, Despite Doctors' Dismissals (Exclusive)Erin Stoop’s daughter Olivia was diagnosed with Sanfilippo syndrome, a terminal genetic disorder, after persistent symptoms were initially dismissed by pediatricians. The family has partnered with the Cure Sanfilippo Foundation and utilized social media to raise over $450,000 for research while advocating for earlier diagnosis and FDA-approved treatments.PR NewswirePerlara announces MPSIII PerlQuests with Cure Sanfilippo FoundationPerlara announced a partnership with the Cure Sanfilippo Foundation to initiate the MPSIII PerlQuests program, aiming to identify repurposable drugs for Sanfilippo Syndrome. The collaboration will utilize Perlara's screening platform and the Microsource Spectrum collection to test compounds on engineered nematode and fly disease models over the next 12 months.